Jazz Pharma sues FDA over approval of rival narcolepsy drug

Seeking to protect its oxybate franchise in the face of a burgeoning branded competitor, Jazz Pharma said it’s suing to have the Food and Drug Administration set aside the approval of Avadel Pharma’s Lumryz.